A heavily pretreated patient with recurrent clear cell adenocarcinoma of the ovary in whom carcinomatous peritonitis was controlled successfully by salvage therapy with gemcitabine (Archives Gynecology and Obstetrics (2008) 278, (565-568) DOI: 10.1007/s00404-007-0396-3);A heavily pretreated patient with recurrent clear cell adenocarcinoma of the ovary in whom carcinomatous peritonitis was controlled successfully by salvage therapy with gemcitabine

Archives of Gynecology and Obstetrics

Volumn 278, Issue 6, 2008, Pages 565-568

  Komiyama, Shin ^a,b   Nakamura, Masaru ^b   Murakami, Isao ^b   Kuwabara, Yoshiko ^b   Kurahashi, Takashi ^b   Tanaka, Kyoko ^b   Mikami, Mikio ^b,c  

^a FUJITA HEALTH UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b SAITAMA NATIONAL HOSPITAL   (Japan)

^c TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Carcinomatous peritonitis; Gemcitabine; Irinotecan; Recurrent clear cell adenocarcinoma of the ovary; Salvage therapy; Stabilization

Indexed keywords

CA 125 ANTIGEN; CARBOPLATIN; CISPLATIN; ETOPOSIDE; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IRINOTECAN; PACLITAXEL; PLATINUM; TAXANE DERIVATIVE;

ADULT; ALLERGY; ANOREXIA; ARTICLE; ASCITES; BLOOD LEVEL; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER STAGING; CARCINOMATOUS PERITONITIS; CASE REPORT; CLEAR CELL CARCINOMA; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG USE; DRUG WITHDRAWAL; FEMALE; HUMAN; HUMAN TISSUE; LEUKOPENIA; LIVER METASTASIS; MALAISE; MONOTHERAPY; NAUSEA; NEUTROPENIA; OVARY ADENOCARCINOMA; PALPATION; RECURRENT CANCER; SALVAGE THERAPY; SPLEEN CANCER; THROMBOCYTOPENIA; VOMITING;

EID: 54349089858     PISSN: 09320067     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00404-008-0863-5     Document Type: Erratum

References (17)

1. B Lund OP Hansen K Theilade M Hansen JP Neijt 1994 Phase II study of gemcitabine (2',2'- difluorodeoxycytidine) in previously treated ovarian cancer patients J Natl Cancer Inst 86 1530 1533
2. JD Shapiro MJ Millward D Rischin M Michael V Walcher PA Francis GC Toner 1996 Activity of gemcitabine in patients with advanced ovarian cancer: responses seen following platinum and paclitaxel Gynecol Oncol 63 89 93
3. M Friedlander MJ Millward D Bell R Bugat P Harnett JA Moreno L Campbell C Varette V Ripoche L Kayitalire 1998 A phase II study of gemcitabine in platinum pre-treated patients with advanced epithelial ovarian cancer Ann Oncol 9 1343 1345
4. G von Minckwitz T Bauknecht CM Visseren-Grul JP Neijt 1999 Phase II study of gemcitabine in ovarian cancer Ann Oncol 10 853 855
5. DF Silver MS Piver 1999 Gemcitabine salvage chemotherapy for patients with gynecologic malignancies of the ovary, fallopian tube, and peritoneum Am J Clin Oncol 22 450 452
6. T Bilgin S Ozalp OT Yalcin G Zorlu MA Vardar K Ozerkan 2003 Efficacy of gemcitabine in heavily pretreated advanced ovarian cancer patients Eur J Gynaecol Oncol 24 169 170
7. M Markman K Webster K Zanotti B Kulp G Peterson J Belinson 2003 Phase 2 trial of single-agent gemcitabine in platinum-paclitaxel refractory ovarian cancer Gynecol Oncol 90 593 596
8. B Piura A Rabinovich 2004 Gemcitabine in heavily pretreated patients with recurrent ovarian, peritoneal and fallopian tube carcinoma Eur J Gynaecol Oncol 25 449 452
9. B Piura 2005 Long-term disease-free survival effected by gemcitabine in a heavily pretreated patient with recurrent ovarian carcinoma Arch Gynecol Obstet 271 182 3
10. T Safra I Ron M Boaz J Brenner D Grisaru M Inbar H Hayat J Menczer A Golan T Levy 2006 Heavily pretreated ovarian cancer patients treated by single-agent gemcitabine. A retrospective outcome comparison between platinum-sensitive and platinum-resistant patients Acta Oncol 45 463 468
11. BA Goff R de Sainz la Cuesta HG Muntz D Fleischhacker M Ek LW Rice N Nikrui HK Tamimi JM Cain BE Greer AF Fuller Jr 1996 Clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy in stage III disease Gynecol Oncol 60 412 417
12. D Pectasides G Fountzilas G Aravantinos C Kalofonos H Efstathiou D Farmakis D Skarlos N Pavlidis T Economopoulos MA Dimopoulos 2006 Advanced stage clear-cell epithelial ovarian cancer: the Hellenic cooperative oncology group experience Gynecol Oncol 102 285 291
13. T Sugiyama T Kamura J Kigawa N Terakawa Y Kikuchi T Kita M Suzuki I Sato K Taguchi 2000 Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy Cancer 88 2584 2589
14. S Pather MA Quinn 2005 Clear cell cancer of the ovary-is it chemosensitive? Int J Gynecol Cancer 15 432 437
15. M Fujimura T Hidaka K Kataoka Y Yamakawa S Akada A Teranishi S Saito 2001 Absence of estrogen receptor-alpha expression in human ovarian clear cell adenocarcinoma compared with ovarian serous, endometrioid, and mucinous adenocarcinoma Am J Surg Pathol 25 667 672
16. DR Schwartz SL Kardia KA Shedden R Kuick G Michailidis JM Taylor DE Misek R Wu Y Zhai DM Darrah H Reed LH Ellenson TJ Giordano ER Fearon SM Hanash KR Cho 2002 Gene expression in ovarian cancer reflects both morphology and biological behavior, distinguishing clear cell from other poor-prognosis ovarian carcinomas Cancer Res 62 4722 4729
17. A Tsuchiya M Sakamoto J Yasuda M Chuma T Ohta M Ohki T Yasugi Y Taketani S Hirohashi 2003 Expression profiling in ovarian clear cell carcinoma: identification of hepatocyte nuclear factor-1 beta as a molecular marker and a possible molecular target for therapy of ovarian clear cell carcinoma Am J Pathol 163 2503 2512